MicroRNA-20b-5p functions as a tumor suppressor in renal cell carcinoma by regulating cellular proliferation, migration and apoptosis

Li,Yifan; Chen,Duqun; Jin,Lu; Liu,Jiaju; Su,Zhengming; Li,Yuchi; Gui,Yaoting; Lai,Yongqing

doi:10.3892/mmr.2015.4692

MicroRNA-20b-5p functions as a tumor suppressor in renal cell carcinoma by regulating cellular proliferation, migration and apoptosis

Authors:
- Yifan Li
- Duqun Chen
- Lu Jin
- Jiaju Liu
- Zhengming Su
- Yuchi Li
- Yaoting Gui
- Yongqing Lai
View Affiliations

Affiliations: Department of Urology, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China, The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China
Published online on: December 17, 2015 https://doi.org/10.3892/mmr.2015.4692
Pages: 1895-1901

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults and is associated with a poor prognosis due to a lack of early‑warning signs, protean clinical manifestations, and resistance to radiotherapy and chemotherapy. Recently, increasing evidence has suggested that microRNAs (miRNAs) are involved in the proliferation, invasion and apoptosis of various types of human cancer cells. In a previous study, miRNA expression profiles from renal cell carcinoma (RCC) revealed that expression of miR‑20b‑5p was significantly downregulated in RCC tissues. The aim of this study was to investigate the expression and functional significance of miR‑20b‑5p in RCC. The expression of miR‑20b‑5p was quantified in 48 paired RCC tissues and cell lines, and compared with adjacent normal tissues and the 293T cell line by reverse transcription‑quantitative polymerase chain reaction. The functional impact of miR‑20b‑5p on cell proliferation, cell migration and apoptosis in the 786‑O and ACHN RCC cell lines, was determined by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, a scratch assay and flow cytometry. To the best of our knowledge, the present study was the first to reveal that miR‑20b‑5p was downregulated in RCC tissues and cell lines. It also demonstrated that upregulation of miR‑20b‑5p inhibited cellular migration and proliferation, and promoted cellular apoptosis, suggesting that miR‑20b‑5p functioned as a potential tumor suppressor. However, further studies are required to fully determine the effects of miR‑20b‑5p and the miR‑20b‑5p‑mediated molecular pathway in RCC and other types of cancer. In conclusion, these results imply that miR‑20b‑5p may be a biomarker for early detection and prognosis prediction, as well as a therapeutic target for RCC.

View Figures

View References

1	Tavani A and La Vecchia C: Epidemiology of renal-cell carcinoma. J Nephrol. 10:93–106. 1997.PubMed/NCBI
2	National Cancer Institute: Surveillance, epidemiology and end results program. SEER stat fact sheets: Kidney and renal pelvis cancer. http://seer.cancer.gov/statfacts/html/kidrp.html. Accessed March 30, 2014.
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 20142014. View Article : Google Scholar : PubMed/NCBI
4	Zhejiang Channel XNA: World Kidney Day: Kidney Cancer incidence increased year by year become 'invisible killer'. Available at: http://www.zj.xinhuanet.com/news-center/science/2014-03/13/c_119759340.htm. Accessed 13 March 2014.
5	Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X and He J: Annual report on status of cancer in China, 2010. Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
6	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
7	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
8	Ridge CA, Pua BB and Madoff DC: Epidemiology and staging of renal cell carcinoma. Semin Intervent Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
9	Huntzinger E and Izaurralde E: Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
11	Perez-Rivas LG, Jerez JM, Carmona R, de Luque V, Vicioso L, Claros MG, Viguera E, Pajares B, Sánchez A, Ribelles N, et al: A microRNA signature associated with early recurrence in breast cancer. PLoS One. 9:e918842014. View Article : Google Scholar : PubMed/NCBI
12	Li JY, Zhang Y, Zhang WH, Jia S, Kang Y and Zhu XY: Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pac J Cancer Prev. 13:1901–1906. 2012. View Article : Google Scholar : PubMed/NCBI
13	Li D, Ilnytskyy Y, Kovalchuk A, Khachigian LM, Bronson RT, Wang B and Kovalchuk O: Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. Oncotarget. 4:1373–1387. 2013. View Article : Google Scholar : PubMed/NCBI
14	Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D and Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 24:652–657. 2009. View Article : Google Scholar : PubMed/NCBI
15	Cheung TH, Man KN, Yu MY, Yim SF, Siu NS, Lo KW, Doran G, Wong RR, Wang VW, Smith DI, et al: Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle. 11:2876–2884. 2012. View Article : Google Scholar : PubMed/NCBI
16	Coskun E, Neumann M, Schlee C, Liebertz F, Heesch S, Goekbuget N, Hoelzer D and Baldus CD: MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. Leuk Res. 37:647–656. 2013. View Article : Google Scholar : PubMed/NCBI
17	Hui AB, Lin A, Xu W, Waldron L, Perez-Ordonez B, Weinreb I, Shi W, Bruce J, Huang SH, O'Sullivan B, et al: Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res. 19:2154–2162. 2013. View Article : Google Scholar : PubMed/NCBI
18	Yamaguchi T, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Nakayama Y, Mori T, Horiguchi S and Miyaki M: Underexpression of miR-126 and miR-20b in hereditary and nonhereditary colorectal tumors. Oncology. 87:58–66. 2014. View Article : Google Scholar : PubMed/NCBI
19	Müller S and Nowak K: Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. Biomed Res Int. 2014:9484082014. View Article : Google Scholar : PubMed/NCBI
20	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer Verlag; New York, NY: pp. 479–489. 2010
21	Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N and Russo A: miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 224:242–249. 2010.PubMed/NCBI
22	Saleiban A, Faxälv L, Claesson K, Jönsson JI and Osman A: miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells. Pigment Cell Melanoma Res. 27:431–441. 2014. View Article : Google Scholar : PubMed/NCBI
23	Visone R and Croce CM: MiRNAs and cancer. Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
24	Voinnet O: Origin, biogenesis and activity of plant microRNAs. Cell. 136:669–687. 2009. View Article : Google Scholar : PubMed/NCBI
25	Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH and Oosterwijk E: Potential role of genetic markers in the management of kidney cancer. Eur Urol. 63:333–340. 2013. View Article : Google Scholar
26	Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 34:537–542. 2009.PubMed/NCBI
27	Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, Zhan R and He X: Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene. 29:2302–2308. 2010. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
29	George DJ and Kaelin WG Jr: The von Hippel-Lindau protein, vascular endothelial growth factor and kidney cancer. N Engl J Med. 349:419–421. 2003. View Article : Google Scholar : PubMed/NCBI
30	Motzer RJ and Basch E: Targeted drugs for metastatic renal cell carcinoma. Lancet. 370:2071–2073. 2007. View Article : Google Scholar : PubMed/NCBI
31	de Martino M, Haitel A, Schatzl G and Klatte T: The protease activated receptor 1 gene variation IVSn-14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma. J Urol. 190:1392–1397. 2013. View Article : Google Scholar : PubMed/NCBI